27th February 2025

A 38-year-old gentleman with renal cell carcinoma is currently receiving treatment with ipilimumab and nivolumab immunotherapy

A 38-year-old gentleman with renal cell carcinoma is currently receiving treatment with ipilimumab and nivolumab immunotherapy.

He had blood tests performed last week as part of his routine monitoring that showed: bilirubin 35 µmol/L (<21 µmol/L), ALP 320 IU/L (30-130 IU/L), ALT 170 IU/L (10-60 IU/L), albumin 40 g/L (35–50 g/L), INR 1.2 (1.0 – 1.3).

Repeat bloods today show: bilirubin 55 µmol/L (<21 µmol/L), ALP 1200 IU/L (30-130 IU/L), ALT 1320 IU/L (10-60 IU/L), albumin 32 g/L (35–50 g/L), INR 1.8 (1.0 – 1.3).

Which of the following would not form part of appropriate management for this patient?

Select the SINGLE most appropriate option from the list below. Select ONE option only.